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The compromised health-related quality of life (HRQOL)
of patients with chronic kidney disease is now well
documented. The recent mandate by the Center for Medicare
Services in the United States that all dialysis units monitor
HRQOL as a condition of coverage has focused attention on
the importance of these measures. The challenge for the
nephrology care team is understanding how to interpret and
utilize the information obtained from these HRQOL
measurements. Can HRQOL of these patients be improved?
The present review addresses this issue by commenting on
strategies that have been used to improve the HRQOL of
chronic kidney disease patients. A systematic approach is
suggested for nephrology care providers to attempt to
evaluate and improve the HRQOL of CKD patients.
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The compromised health-related quality of life (HRQOL)
of patients with end-stage renal disease (ESRD) is now
well documented.1–7 Numerous studies and reviews have
addressed this subject, using a variety of tools and
instruments to assess the degree of impairment.1–7 The
reliability, validity, and reproducibility of many of these tools
have now been established. The importance of systematically
evaluating this impairment is underscored by the association
of various HRQOL measures with morbidity and mortality
of ESRD patients.1–5 In addition, as Fukuhara et al.7 have
suggested, nephrologists must look not only at biological
outcomes but also at the patient’s perceptions of their quality
of life to properly assess patient status. Thus, the use of
measuring HRQOL as a primary outcome of various
interventions in ESRD treatment regimens is increasingly
being accepted. In fact, it is now mandated in the United
States by the Center for Medicare Services that dialysis
facilities perform routine measurements of HRQOL prefer-
entially using the Kidney Disease Quality of Life-36
(KDQOL-36) questionnaire; additional instruments may
be used.8 These measurements are to be done at regular
intervals, defined as within 4 months of the initiation of
treatment, and then at least annually or more often if
indicated by a significant life changing event. But, what is
the clinician to do with this information and how will it be
used? How will the measurement of HRQOL assist the
clinician to manage the patient and modify and improve
treatment? The mandate from the Center for Medicare
Services indicates that ‘to address the psychosocial needsy
each patient’s plans of care y must include interventions
individualized to meet the patient’s psychosocial needs and
aimed at optimizing the patient’s adjustment to kidney
failure and its treatment.’8
Quality of life has been defined by the World Health
Organization as an individual’s perception of their position
in life in the context of the culture and value systems in which
they live and in relation to their goals, expectations,
standards, and concerns. Health-related quality of life can
be defined as the extent to which one’s usual or expected
physical, social, or emotional well-being (quality of life) is
affected by a medical condition and/or its treatment. HRQOL
includes physical, social, psychological, and therapy-related
components, as summarized in Figure 1.
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ASSESSMENT OF HRQOL
Instruments used to assess HRQOL involve both subjective
and objective measures. Subjective assessments involve
patient-reported outcomes, which can be defined as mea-
surements of any aspect of a patient’s health status that comes
directly from the patient, without the interpretation of the
response by a health care provider. The importance of patient
perceptions of their own physical and mental functioning has
been emphasized. Thus, the recommended HRQOL assess-
ments in the United States involve a patient-reported
outcome. The value of patient reports as opposed to clinician
assessments is underscored by the well-documented discre-
pancies between ESRD patient and health care provider
assessments of problems and difficulties.9 As a result, several
investigators have emphasized the significance of patient
assessments, suggesting that the patient himself is the expert
when it comes to assessing his/her own quality of life.10 These
researchers have stressed eliciting from the patient domains
and concerns that may be unique to their own experience—
not simply relying on generic categories included in
standardized HRQOL instruments.10 This is particularly
important, as it permits the formulation of effective
treatment strategies for the individual patient. On the other
hand, the medical team may need to include objective
assessments of patient status to evaluate the impact of health
on quality of life and formulate clinical intervention
strategies. For example, physical functioning can be assessed
by patient reporting or documented by a variety of objective
measures, such as 6 min walking test or treadmill exercise
testing.11 Moreover, depressive symptoms can be assessed by
a variety of self-reporting instruments such as the Beck
Depression Inventory, Patient Health Questionnaire-9, and
so on. However, establishing a diagnosis of clinical depression
according to standard Diagnostic and Statistical Manual of
Mental Disorders 4 criteria involves a direct patient,
structured interview using an objective, and evidence-based
scoring system.2 This objective evaluation of depression by a
trained interviewer is essential to formulate an effective
treatment plan and to evaluate the impact of interventions.2
The HRQOL areas of difficulty most frequently cited for
chronic kidney disease patients include cognitive dysfunc-
tion, depression, anxiety, pain, sleep disturbance, reduced
physical functioning, sexual dysfunction, reduced social
interaction, reduced global perception of general health or
overall quality of life, and a variety of other symptoms
commonly noted in ESRD patients, such as muscle weakness,
restless legs, post-dialysis fatigue, and so on. In fact, it is
noteworthy that these domains are now being carefully
tracked in a prospective study in the United States of incident
dialysis patients, as noted in a recent study design outlined by
Kutner et al.12 Importantly, several of these domains have
been associated with increased morbidity and mortality. For
example, dialysis patients who report a reduced general
perception of health have a nearly threefold higher risk of
hospitalization or death.5 Hemodialysis (HD) patients and
peritoneal dialysis (PD) patients with increased depressive
symptomatology have a nearly twofold increase in mortality
rates and a twofold higher peritonitis rate, respectively, than
patients who report a lower incidence of symptoms.13,14 In
addition, HD patients who meet standard psychiatric criteria
for clinical depression, based on a structured interview,
have a twofold greater chance of death or hospitalization
than patients who are not clinically depressed.2 Studies
using generic HRQOL instruments, such as the SF-36, have
indicated that reduced scores in HD patients are associated
with significantly higher hospitalization rates and mortality.
For example, reduced physical component summary scores
(o25) on the SF-36 Health Survey have been associated with
nearly twofold greater chance of death and a 60% greater
chance of hospitalization than patients (after corrections for a
variety of standard variables) with scores 446 in studies
involving several thousand HD patients in the Dialysis
Outcomes and Practice Patterns Study.1
INTERVENTIONS TO IMPROVE HRQOL
A major challenge for the medical team is how to clinically
use data obtained from measurements of HRQOL. This will
be a particular issue for nephrologists in the United States, as
they are now mandated to routinely assess HRQOL, as noted
above. Little guidance is provided by the literature, as few
studies have documented interventions that result in
significant improvements in HRQOL scores; some important
clinical trials have in fact shown that major modifications in
treatment regimens do not impact on HRQOL measure-
ments. For example, data from the Adequacy of Peritoneal
Dialysis in Mexico study indicated that improving small
molecule clearances in a large cohort of chronic PD patients
did not result in an improvement in HRQOL scores, when
using the Kidney Disease Quality of Life Short Form as the
assessment tool.15 The HEMO trial also suggested no or
minimally significant changes in HRQOL measures by
increasing the eKT/V urea of HD patients from 1.05 to 1.45
or by using high flux membranes, when using the Index of
Well-Being and the Kidney Disease Quality of Life-Long
Form questionnaires.16 Moreover, cross-sectional and pro-
spective studies comparing PD and conventional, 3 times per
week HD patients have not shown consistent effects
attributable to the dialysis regimen.17,18 The most striking
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Figure 1 |Domains encompassed in health-related quality of
life assessments.
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difference seems to be in the satisfaction with therapy and
the impact of therapy on the lives of patients, with PD
patients generally reporting better satisfaction and a less
negative impact of the therapy than the conventional HD
patients.17,19,20
What interventions, then, have been shown to positively
impact on ESRD patients’ HRQOL measurements? A few
studies, some preliminary, have suggested that treatment
of anemia, exercise programs, treatment of depression,
and selected modifications in the dialysis treatment
regimen have resulted in improved HRQOL assessments.
Treatment of sleep disturbances and pain may also have a
positive effect. In addition, counseling in response to
individual patient issues and cognitive behavioral therapy
can be helpful. Finally, there are lessons to be learned from
health psychology.
The relationship between anemia and HRQOL has been
the subject of extensive study. The interpretation of these
studies has been complicated by the recent United States
Food and Drug Administration hearing concerning erythro-
poetic-stimulating agents and CKD patients. This hearing
suggested that hemoglobin levels over 12 g% may be
associated with increased morbidity and mortality, and that
the HRQOL benefits of these drugs have not been established,
as the studies investigating this relationship were not
satisfactorily done.21 However, two recent articles re-exam-
ined this issue and both came to similar conclusions.22,23 A
detailed review by Leaf and Goldfarb22 concluded that
erythropoetin therapy resulted in significant improvements
in various HRQOL domains. In studies using the SF-36
Health Survey domains, the most dramatic improvements
were noted in physical symptoms, vitality, energy, and
performance. Smaller improvements were noted in social
functioning and mental health, and little, if any, improve-
ment in emotional health or pain. The maximal increase in
HRQOL per change in hemoglobin level occurred in the
range of 10–12 g%. These findings were virtually identical to
the results reported in a large cross-sectional analysis
studying the relationship between hemoglobin levels and
HRQOL in 1200 CKD patients not on dialysis.23 Additional
domains showing possible improvements with erythropoetin
therapy include sleep, cognitive functioning, and sexual
functioning.22
There has been considerable interest in the impact of
modifications of the dialysis regimen on a variety of
outcomes of ESRD patients maintained on HD.24–34 These
regimens include short daily HD done at home or in-center,
and nocturnal HD done three or more times per week at
home or in-center. Several studies have suggested improve-
ments in selected medical outcomes with these regimens,
including improved blood pressure control and need for anti-
hypertensive medications, reduced phosphate levels, and
lower ultrafiltration rates.
The impact of these newer regimens on HRQOL has
generated much interest.24–34 Studies examining the impact
of more frequent HD on HRQOL have been somewhat
difficult to interpret because a wide variety of instruments
have been used, the findings have not been consistent, the
patients have in general not been randomized, and the
number of patients studied has been small. However, in
general, the findings suggest that selected domains are
impacted by more frequent HD.24–34 These include sleep,
depressive symptoms, global quality of life assessment,
patient satisfaction, general health perception, cognitive
dysfunction, and other selected domains that may not be
well covered in standard HRQOL instruments.29,33 Impor-
tantly, some investigators have suggested that to fully evaluate
the impact of more frequent HD, it is important to listen to
what individual patients report, as the impact that the change
in therapy is having on their lives may not be captured by
standardized HRQOL instruments.29,33 The positive impact
of the newer treatment regimens on patient-reported
outcomes needs to be balanced by the burden of the
therapy—in terms of the impact on both the patient as well
as the caregiver.
Various HRQOL measures have been included as primary
and secondary end points in recent trials evaluating these
new regimens. For example, in the National Institutes of
Health sponsored Frequent Hemodialysis Network Trial
comparing conventional HD to 6 times per week in-center
HD and 5–6 times per week nocturnal home HD, one of the
two primary outcomes is a composite of the physical health
composite score of the SF-36 and mortality; three of the nine
secondary outcomes involve HRQOL measures (Beck Depre-
ssion Inventory, Trailmaking B test, and the physical
composite score).24 The Following Rehabilitation, Economics
and Everyday-Dialysis Outcome Measurements (FREEDOM)
Study is designed to evaluate 500 patients with 6 times per
week short daily HD using the NxStage dialysis machine
(NxStage Medical, Lawrence, MA, USA).25 Mortality, hospi-
talizations, and costs will be compared with 5000 matched
patients in the USRDS database. HRQOL domains being
monitored in the 500 NxStage patients include the SF-36,
Beck Depression Inventory, global assessment of quality of
life and physical intimacy, time to recovery after a dialysis
session, and symptoms of sleep difficulties and restless legs.
One of the most dramatic changes in patient-reported
outcomes with more frequent HD is the time to recover after
a dialysis session (that is, How long does it take to resume
usual activities after completion of a dialysis treatment?).26
Lindsay et al.26 have reported dramatic decreases in the time
to recovery for patients treated with more frequent dialysis.
Thus, patients maintained on conventional 3 times per week
HD report an average recovery time of about 6 h, whereas
patients converted to more frequent short daily or nocturnal
HD report less than 1 h recovery time. This change strongly
correlates with improvements in various HRQOL domains.
These associations include the physical and mental compo-
nent scores as well as seven of the eight domains of the SF-36
Health Survey, five domains of the Health Utility Index,
and the majority of the subscales on a dialysis stress
questionnaire.26
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A recently reported randomized trial from Alberta of
five or six times per week nocturnal HD compared with
conventional HD examined a variety of HRQOL outcome
measures.27,28 These included the European Quality of Life
5D Index Score (a measure of overall quality of life), the
European Quality of Life visual analog scale (global health
perception), and four domains from the Kidney Disease
Quality of Life (burden of kidney disease, effects of kidney
disease, and sleep and kidney disease-related symptoms and
problems). After 6 months of therapy, there were not
significant changes in the European 5D Index Score or
visual analog scale, but a significant improvement in the
effects of kidney disease (8.6 point increase) and burden of
kidney disease (9.8 point increase). In addition, there were
non-significant improvements in all domains of the SF-36,
including the physical component score and mental compo-
nent score.
Preliminary data from the FREEDOM study have also
suggested an improvement in a variety of HRQOL domains.
A 4-month interim analysis of 78 patients (planned in the
initial study design) has indicated a significant decrease in
Beck Depression Inventory scores (12.6 to 8.3), increases in
physical and mental components scores from the SF-36
Health Survey, and dramatic reductions in time to recovery
after a dialysis session from 568 to 65 min.30 The improve-
ment in Beck Depression Inventory scores and time to
recovery was sustained at 12 months after initiation of 6
times per week home HD.31
Another domain associated with impaired HRQOL that
has been reported to improve with more frequent HD is sleep
difficulties.34,35 Sleep disturbances are common in ESRD
patients; in a Dialysis Outcomes Practice Patterns Study
examining over 11,000 HD patients, 49% were judged to
experience poor sleep quality using a self-reported sleep
questionnaire.35 Impaired sleep quality was associated with
significantly lower physical and mental component scores,
after standard corrections for various co-morbidities.35
Treating the sleep disturbances of ESRD patients has proven
to be challenging and is an area that requires further study.
Thus, the reports of the impact of more frequent, nocturnal
HD on sleep apnea are of interest.34 Converting patients from
conventional 3 times per week HD to nocturnal HD 6 or 7
times per weeks resulted in a reduction in the frequency of
apnea and hypopnea from 25±25 to 8±8 episodes per hour
of sleep (P¼ 0.03).34
Cognitive dysfunction is commonly noted in ESRD
patients. The management of this difficult problem generally
consists of optimizing medical and psychosocial care. The
potential positive impact of nocturnal HD on cognitive
function is, therefore, of considerable interest. A recent report
examining just 12 patients suggested that nocturnal HD may
be associated with improved general cognitive efficiency as
measured by tests focusing on psychomotor efficiency and
attention, and working memory.36
Depression is a major problem for CKD patients.2–4,37–39
Depression is well documented to be the most common
psychological problem of dialysis patients; between 25 and
30% of ESRD patients have a diagnosis of clinical depres-
sion.2,37 The presence of depressive symptoms is associated
with increased morbidity and mortality, as discussed above,
and has been associated, not surprisingly, with reduced
HRQOL scores.4,37 Few studies have systematically studied
the treatment of depression in CKD patients.2,37,38 It is
important to recognize that before the treatment of
depression is planned, a diagnosis of clinical depression
needs to be established by direct patient interviews.2,37–39 The
use of questionnaires, such as the Beck Depression Inventory,
indicates the presence of depressive symptoms. But, the
diagnosis of clinical depression requires a structured inter-
view using standard psychiatric criteria.2,39 Once the
diagnosis is established, then treatment can be considered.
Various treatment regimens for depression of chronic kidney
disease patients have been described.37–42 Anti-depressant
medications have been used and have been reported to result
in significant improvement in depressive symptomato-
logy.37,38 However, it is challenging to establish an effective
pharmacological treatment program of ESRD patients for a
variety of reasons. Patients are often unwilling to complete
the evaluation for depression, are reluctant to take additional
medications, and may not complete a course of therapy.37,38
Non-pharmacological treatment of depression, using psy-
chotherapy, exercise therapy, and cognitive behavioral
therapy have met with some success in small series.39–42 Of
particular note is a recent randomized trial of cognitive
behavioral therapy, presented in abstract form, in which 85
dialysis patients with clinical depression diagnosed by
interview were randomized to standard care or standard care
with cognitive behavioral therapy with a psychologist.40
There was an 80% compliance with the treatment regimen,
and after 3 months of treatment, there was a significant
difference in the Beck Depression scores between the
treatment and control groups (14.1±8.7 vs 21.2±9.1,
respectively, Po0.01).40 Of particular note, there was a
significant improvement in several domains on the KDQOL-
SF, including burden of kidney disease, overall health, social
interaction, sleep, and mental component score.40 This
preliminary study, therefore, suggests that psychological
interventions, such as cognitive behavioral therapy, counsel-
ing, stress reduction, and so on, can be useful in reducing
depressive symptoms and improving HRQOL, as is well
documented in other disease states.
Structured exercise programs may also have a beneficial
effect on HRQOL in chronic kidney disease patients.11,41–42
The reduced physical functioning of patients can in part be
ameliorated with exercise programs which in turn can result
in an improvement of various HRQOL parameters.11,41–42
For example, in one recent study, a 12-week program of
90 min/day, 3 times per week exercise in a cohort of HD
patients resulted in a significant reduction in depression
scores (Po0.001) and improvement in the physical and
mental component scores of the SF-36 Health Survey
(P¼ 0.002 and P¼ 0.004, respectively).41 In another recent
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study, 35 HD patients were randomized to a 10-month
intradialytic exercise training program or standard care.42
There was a dramatic increase in exercise capacity in the
study group (nearly 25% increase in their aerobic capacity
and exercise time) associated with a 40% reduction in Beck
Depression Inventory scores and increase in Life Satisfaction
Index and physical component score (40.5–44.5).42
Studies have also noted an association between sexual
dysfunction and a variety of other quality of life parameters,
such as various mental and physical components of the SF-36
and depression scores.43–48 These studies raise the question of
whether specifically addressing the sexual dysfunction of
patients could have a positive impact on their quality of life
measures.43–48 For example, recent studies have shown that in
men with mild-to-moderate depressive illness, an improve-
ment in erectile dysfunction is associated with significant
improvement in not only depressive symptoms but quality of
life assessments as well.43 Thus, systematic evaluations of
sexual difficulties of chronic kidney disease patients and
strategies to address these difficulties need to be incorporated
into evaluations of HRQOL of patients with chronic kidney
disease.44–48
The psychosocial impact of pain for chronic kidney
disease patients is another area that needs further explora-
tion.49,50 Chronic pain is a common complaint for patients
with ESRD. The pain is often moderate or severe, and
significantly impacts virtually every aspect of HRQOL.49,50
Unfortunately, there has been limited clinical research in this
area. Pain in ESRD patients is often undertreated, in part
because of the reluctance of nephrologists to prescribe
narcotics to patients with kidney disease. The challenges of
developing safe and effective treatment regimens for the often
complex ESRD patient has recently been reviewed.49
Stress for patients with kidney disease may be burden-
some. There are a variety of stressors that impact on the life
of a dialysis patient.51 These stressors may include the impact
of the illness on overall functioning, dietary issues, loss of
supportive structures and relationships, loss of employment,
financial difficulties, time constraints, mood fluctuations,
functional limitations, and fear of disability and death.
Adaptive coping mechanisms are needed to deal with these
complex changes in patients’ lives. In the absence of adequate
coping strategies, these stressors can aggravate the patients’
perception of their quality of life. It is important, therefore,
for the nephrology team to be aware of these areas of
difficulty and explore coping mechanisms with the patient.
Anxiety is also commonly noted in ESRD patients; 27% of
urban HD patients have a major anxiety disorder.52 The
presence of an anxiety disorder is associated with a
significantly lower overall perceived quality of life
(Po0.05).52 Evaluating and understanding anxiety in the
ESRD patient may open therapeutic avenues to explore,
which may positively impact on HRQOL.
Social support has been shown to correlate with a variety
of HRQOL domains, including depressive symptoms,
perception of illness effects, satisfaction with life, and overall
quality of life of ESRD patients.53,54 Marital and family
discord are commonly observed in ESRD patients and may
negatively impact on HRQOL.45,55,56 Active community
support, including spiritual involvement, has been associated
with improved HRQOL assessments.57,58 However, as
pointed out by Cohen et al.,54 few studies have examined
the impact of social support interventions in ESRD patients
and these studies have been limited by small sample size, lack
of appropriate controls, and a retrospective analysis.
The impact on the caregivers who provide support for
patients with CKD and ESRD is an area that has received
surprising little attention.59,60 Of note is a recent systematic
literature review that noted only three articles that describe
interventions for caregivers of CKD patients; all assess the
effect of educational material given to the caregiver and
describe an improvement of knowledge with no report of
other outcomes.54 Importantly, lessons from other chronic
diseases have suggested that exploring ways of supporting
caregivers can have beneficial effects on the outcomes for
both the patient and the caregiver.59,60
CONCLUSION
In summary, there is an increasing interest in assessing
HRQOL in patients with chronic kidney disease. Importantly,
it is now mandated in the United States that HRQOL
measurements be done routinely on all ESRD patients. The
interpretation and use of the information obtained from
these HRQOL assessments pose certain challenges for the
nephrology care team. The focus clearly needs to be on
developing strategies to improve the compromised HRQOL
of the patient with chronic kidney disease. To address this
properly requires that careful assessments be done in a variety
of domains (outlined in Table 1) and that the interventions
use the resources of the entire patient care team (physicians,
nurses, social workers, dieticians, psychologists, techni-
cians, physical rehabilitation therapists, family, community
resources, religious organizations, and so on). It will be
important to document that interventions can positively
Table 1 | Strategies to improve health-related quality of life of
the chronic kidney disease patient
1. Assessment of patient symptom burden using patient reported
measures: formulation of treatment options
2. Optimization of medical therapy
3. Review social support systems
4. Management of anemia: maintenance of hemoglobin levels in 11–12
range
5. Treatment of depression: medication, counseling, and/or other
strategies
6. Modifications in dialysis treatment regimen: more frequent
hemodialysis
7. Physical functioning: utilization of exercise programs
8. Assessment and treatment of sleep disturbances
9. Assessment and treatment of pain
10. Assessment and treatment of stress and anxiety
11. Assessment and treatment of sexual dysfunction
12. Assessment of cognitive dysfunction with appropriate support
13. Caregiver assessment and support
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impact on the HRQOL, as they have in other health care
arenas. Enlisting patient cooperation in participating in these
investigations and interventions will require careful attention
and thought; this may well prove to be difficult and require
creative ways of engaging the patient. In addition, identifying
the financial resources to provide appropriate interventions
will require strategic planning. Certainly, if the interventions
translate into improved medical outcomes and reduced
hospitalizations, then funding to support these programs
should not be difficult to arrange. Thus, carefully tracking the
impact of these interventions on not only HRQOL but also
medical outcomes, hospitalizations, and the global cost of
care is essential.
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